How Clinical Research Is Funded

Ask a data manager why a study runs on the system it runs on, with the staffing it has, on the timeline it follows, and the honest answer is rarely "best practice." It is usually "the budget." Who pays for clinical research — and on what terms — shapes what data is collected, which systems collect it, who cleans it, and what happens to it afterward. This guide introduces that funding environment.

Broadly, clinical research is paid for in two ways that produce two recognizably different working worlds: academic and investigator-initiated research, funded by grants, foundations, and institutions; and commercially sponsored research, funded by companies developing products. Many organizations — and many careers — straddle both, a divide we examine at length in Academic vs. Commercial Clinical Research.

The funding lifecycle

Funding is a process, not an event, and it runs in parallel with the study itself:

An investigator finds an opportunity or a sponsor identifies a development need; the application or proposal is qualified and submitted; an award or contract follows; setup, conduct, documentation, and reporting consume the award period; and renewal or follow-on funding restarts the cycle. Data management obligations attach at nearly every stage — most consequentially at the beginning, when budgets are set, and at the end, when reporting and data sharing come due.

Academic and investigator-initiated funding

• NIH grants. The dominant public funder of biomedical research in the United States. NIH funds through defined mechanisms — among the most common, the R01 research project grant, smaller R-series awards such as the R21, career development K awards, and cooperative agreements (U mechanisms) in which NIH staff participate substantially ^[2]. Awards are made to institutions, run in multi-year budget periods, and carry progress-reporting obligations.
• The NIH Data Management and Sharing Policy. Effective January 2023, NIH requires a Data Management and Sharing Plan in applications and expects funded researchers to maximize appropriate sharing of scientific data ^[1]. For data managers this policy moved planning questions — formats, standards, de-identification, repositories, preservation — from afterthought to application requirement, with allowable costs budgetable in the proposal ^[1].
• Other federal funders. Other HHS agencies, the Department of Defense, the Department of Veterans Affairs, and agencies outside HHS also fund clinical research, each with its own mechanisms and data requirements.
• Foundations and disease-focused nonprofits. Often faster and more flexible than federal funding, frequently focused on specific conditions, and increasingly carrying their own data-sharing expectations.
• Institutional and internal funds. Departmental startup packages, pilot programs, and internal awards — commonly the seed money that produces the preliminary data a larger grant application needs.
• Registries and networks. Long-running cohort studies and research networks funded through cooperative agreements or consortium arrangements, where infrastructure — including the data platform — is itself a funded deliverable.

Commercial sponsorship

Commercially sponsored trials are paid for by the company developing the drug, device, or diagnostic, as part of a development program whose endpoint is regulatory submission and marketing. The money moves differently:

• Sponsor budgets. The sponsor funds the whole apparatus — protocol development, systems, monitoring, data management, statistics — either in-house or through vendors.
• CRO contracting. Sponsors routinely contract research organizations (CROs) to run some or all of a trial. Data management is a common outsourced function, priced into a scope of work with unit assumptions (pages, queries, listings) that become very concrete when the study changes.
• Per-site and per-subject economics. Sites are typically paid under clinical trial agreements with per-subject payments tied to completed, documented visits — plus startup fees and invoiceable items. The documented visit is the billable event, which is one reason enrollment and site metrics and clean visit data get executive attention in industry trials.
• Registration and reporting obligations. Applicable clinical trials must be registered and have results reported on ClinicalTrials.gov under FDAAA — an obligation that falls on academic and commercial sponsors alike ^[3].

Distinctions that matter

• Grant. Support for a research purpose proposed by the investigator, with accountability for conducting the work as proposed.
• Contract. Purchase of defined work — common in commercial research and in some government procurement — where the funder specifies the deliverables.
• Cooperative agreement. A grant with substantial funder involvement in the conduct of the work ^[2].
• Direct costs. Costs attributable to the project: staff effort, systems, per-subject payments.
• Indirect costs (F&A). Facilities and administrative costs recovered by the institution at a negotiated rate on top of (most) direct costs — a perennial point of tension, because much research infrastructure lives in this layer.
• Per-subject payment. Site compensation tied to enrolled participants and completed visits, which links revenue directly to data completeness.

How funding shapes data management

Funding is not just money in; it is constraints attached to the money. In our assessment, the funding source is among the strongest predictors of a study's data management choices:

• System selection. A modest investigator grant makes an institutionally licensed system such as REDCap the default; a sponsored regulated trial budgets for commercial EDC, usually chosen by the sponsor. We treat this decision fully in REDCap, Commercial EDC, or a Configurable Research Platform?
• Staffing. Grant budgets fund fractional coordinator and data manager effort spread across studies; commercial budgets fund dedicated data management teams, in-house or at a CRO. The same cleaning task exists in both worlds — the question is whose time is funded to do it.
• Timelines. Grant cycles reward getting preliminary data before the next submission deadline; commercial programs reward database lock dates tied to development milestones. Both pressures land on data management — usually as compressed build and testing time, a failure pattern we describe in From Protocol to Database Lock.
• What must be kept and shared. Federal awards carry data management and sharing plans ^[1]; commercial trials carry sponsor retention and submission requirements; both carry registration and results reporting where applicable ^[3]. All of it lands on export, de-identification, and archiving capabilities.

Funding challenges

• Budget cycles vs. study reality. Multi-year studies live inside annual budget periods, continuing resolutions, and renewal uncertainty. Data continuity — keeping a system licensed and a database maintained between awards — is a recurring, rarely glamorous problem.
• Infrastructure falls between the cracks. Grants fund studies; institutions fund infrastructure from indirect cost recovery; and data management platforms, training, and standards work sit awkwardly between the two.
• Mandates without matching budgets. Data-sharing expectations have grown faster than the budgeting norms to pay for them. NIH allows DMS costs in proposals ^[1], but curation, de-identification, and repository deposit for studies designed before these norms — or funded by sources without such provisions — often become unfunded end-of-study work.
• The amendment problem. Protocol amendments change scope in both worlds: in grant-funded research the extra data management work is absorbed by existing staff; in CRO contracts it becomes a change order. Neither is free, but only one is visible.

Where to go deeper

Academic vs. Commercial Clinical Research develops the two-worlds comparison across culture, staffing, and systems, and The Two Lifecycles of Clinical Research shows where funding intersects the study and data lifecycles. For what the money ultimately has to pay for, start with What Is Clinical Research Data Management?